<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref76">
 <mixed-citation publication-type="journal" id="cit76">
  <name>
   <surname>Haga</surname>
   <given-names>S.</given-names>
  </name>; 
  <name>
   <surname>Nagata</surname>
   <given-names>N.</given-names>
  </name>; 
  <name>
   <surname>Okamura</surname>
   <given-names>T.</given-names>
  </name>; 
  <name>
   <surname>Yamamoto</surname>
   <given-names>N.</given-names>
  </name>; 
  <name>
   <surname>Sata</surname>
   <given-names>T.</given-names>
  </name>; 
  <name>
   <surname>Yamamoto</surname>
   <given-names>N.</given-names>
  </name>; 
  <name>
   <surname>Sasazuki</surname>
   <given-names>T.</given-names>
  </name>; 
  <name>
   <surname>Ishizaka</surname>
   <given-names>Y.</given-names>
  </name>
  <article-title>TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds</article-title>. 
  <source>Antiviral Res.</source>
  <year>2010</year>, 
  <volume>85</volume>, 
  <fpage>551</fpage>â€“
  <lpage>555</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2009.12.001</pub-id>.
  <pub-id pub-id-type="pmid">19995578</pub-id>
 </mixed-citation>
</ref>
